Eight patients with pancreatic neoplasia were confirmed by surgery or fine-needle aspiration (10% yield of screening); of these, six patients had benign intraductal papillary mucinous neoplasms (IPMNs), one had an IPMN that progressed to invasive ductal adenocarcinoma, and one had a PanIN-1.
The Food and Drug Administration has approved Velcade to treat a type of cancer called multiple myeloma. Velcade should only be used in people who have already been treated with two other types of chemotherapy (drugs used to kill cancer cells), and whose cancer has still progressed on the most recent therapy.Velcade is a new type of cancer drug called a proteasome inhibitor.Proteasomes are enzymes found in cells, and play a role in regulating cell function and growth. Velcade blocks the activity of proteasomes. This blockade can lead to death of cancer cells.elcade is a new type of cancer drug called a proteasome inhibitor. Proteasomes are enzymes found in cells, and play a role in regulating cell function and growth. Velcade blocks the activity of proteasomes. This blockade can lead to death of cancer cells.
FACTREL is a sterile injectable solution of gonadorelin hydrochloride, and when used with LUTALYSE (dinoprost tromethamine) as part of a synchronization regimen, the drug can be used to synchronize estrous cycles to allow fixed time artificial insemination in lactating dairy cows.FACTREL is already approved for the treatment of cystic ovaries in cattle.). The recommended intramuscular dosage is 100 to 200 mcg of gonadorelin (2 to 4 mL) per cow, used in estrous synchrony programs similar to the following: 1  Administer the first dose of FACTREL (2 to 4 mL) at Day 0.